New progress of anti-CD20 monoclonal antibody therapy for children with idiopathic refractory nephrotic syndrome
10.16571/j.cnki.1008-8199.2017.03.020
- VernacularTitle:抗CD20单克隆抗体在儿童原发性难治性肾病综合征的应用新进展
- Author:
Xiang FANG
;
Xiao YANG
- Keywords:
Nephrotic syndrome;
Anti-CD20 monoclonal antibody;
Rituximab;
Immunosuppressive agents;
Children
- From:
Journal of Medical Postgraduates
2017;30(3):315-318
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic Refractory Nephrotic Syndrome (IRNS) has been an intractable problem in clinical treatment .Anti CD20 monoclonal antibody is a new type of immunosuppressive agent , which can induce the lysis and apoptosis of B cells .Significant-ly, it improves the prognosis of IRNS patients .In recent years, a number of case studies and clinical trials have been conducted on the effectiveness of anti CD20 monoclonal antibody in the treatment of children with IRNS .In this paper, the mechanism, clinical applica-tion, adverse effects and problems in the study of anti CD 20 monoclonal antibody in IRNS will be reviewed .
